Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.91 |
| ▸ | MAOA | P21397 | 1/20 | 0.83 |
| ▸ | MAOB | P27338 | 1/20 | 0.83 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6809124 | 0.98 | DPP4 (0.88) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Water SCHEMBL7260926 | 0.98 | DPP4 (0.88) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL294582 | 0.95 | DPP4 (1.00) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL294761 | 0.93 | DPP4 (0.96) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL6809143 | 0.93 | DPP4 (0.96) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL3520274 | 0.91 | DPP4 (0.92) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL1492704 | 0.91 | MAOB (1.00) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Carbamic Acid SCHEMBL10009301 | 0.90 | DPP4 (0.75) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| Hydrochloric Acid SCHEMBL6813615 | 0.88 | MAOB (0.95) | DPP4MAOAMAOBTAAR1SLC6A3 | |
| SCHEMBL17906490 | 0.88 | SLC6A3 (0.89) | DPP4MAOAMAOBTAAR1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103002897-B | Certain amino-pyridazines, compositions thereof, and methods of use thereof | 赛特凯恩蒂克公司 | 2017-06-09 | — | — | CN | claimed |
| EP-2797870-B1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING 1-[1-PHENYL-CYCLOBUTYL]ISOBUTYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10035761-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | Revivia Pharmaceuticals, Inc. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180127362-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9695116-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| CN-103145715-B | Huge ring carboxylic acid and acyl sulfonamides as HCV replication inhibitors | F·霍夫曼-罗须公司 | 2016-08-03 | — | — | CN | disclosed |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | REVIVA PHARMACEUTICALS INC (US) | 2016-04-28 | — | — | US | disclosed |
| US-9296681-B2 | Cycloalkylmethylamines | REVIVA PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9238625-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9096515-B2 | Methods of using cycloalkylmethylamine derivatives | REVIVA PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-0900207-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998034921-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1998-08-13 | — | — | WO | disclosed |
| WO-1997040024-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 1997-10-30 | — | — | WO | disclosed |
| US-5476846-A | Administering anti-thrombotic and anti-asthmatic agent | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1995-12-19 | — | — | US | disclosed |
| US-5387709-A | Bronchodilator agents, anticoagulants, vasodilation | LIPHA LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1995-02-07 | — | — | US | disclosed |
| EP-0472449-B1 | Substituted sulfonamides, processes for their preparation and medicines containing them | LIPHA (FR) | 1994-09-14 | — | — | EP | disclosed |
| EP-0472449-A2 | Substituted sulfonamides, processes for their preparation and medicines containing them | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1992-02-26 | — | — | EP | disclosed |
| US-4755594-A | N6 -substituted adenosines | WARNER-LAMBERT COMPANY (US) | 1988-07-05 | — | — | US | disclosed |
| EP-0232813-A2 | N6-substituted Adenosines | WARNER-LAMBERT COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035761-B2 | Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives | PNMT, HTR6, COMT | DPP4 95/4885MAOA 36/4885MAOB 64/4885 |
| US-20160115121-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | DPP4 95/4885MAOA 36/4885MAOB 64/4885 |
| US-20180127362-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES | PNMT, HTR6, COMT | DPP4 95/4885MAOA 36/4885MAOB 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.